The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced on March 5, 2025.

Convertible debenture:  15 unsecured ACP-01 therapy convertible debenture units for a gross principal of $517,230 (U.S.)

Conversion price:  Each debenture unit is transferable, saleable, subject to a right of first refusal by the company, willable and convertible at the option of the subscriber into: (i) one ACP-01 therapy service on a first-purchased basis; or (ii) common shares of the company at a conversion price of 15.5 cents per Sshare.

Maturity date:  Dec. 31, 2029

Interest rate:  6 per cent per annum

Finder's fee:  356,298 non-transferable finder warrants issued to an arm's-length finder, exercisable into shares at an exercise price of 15.5 cents for a period of 12 months from the date of issuance

Disclosure:  March 5, 2025, June 26, 2025, and July 23, 2025